Trial Profile
A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM 31510 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Basal cell cancer; Leukaemia; Lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Wounds
- Focus Pharmacokinetics
- Sponsors Berg Pharma
- 07 Jan 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2015 New trial record